Avid Bioservices, Inc. (CDMO)
$
12.49
Key metrics
Financial statements
Free cash flow per share
0.0025
Market cap
798.9 Million
Price to sales ratio
5.3103
Debt to equity
4.5868
Current ratio
1.3014
Income quality
0.0226
Average inventory
28.6 Million
ROE
-1.7654
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Avid Bioservices, Inc., a contract development and manufacturing organization, is focused on the biopharmaceutical industry, particularly in the production of drug substances derived from mammalian cell cultures, including monoclonal antibodies and recombinant proteins. The operating income ratio is -0.13 indicating the company's operational profitability margin. Despite its focus on providing CGMP clinical and commercial drug substance manufacturing, along with additional services such as bulk packaging, release and stability testing, and regulatory submission and support, the company reported a net loss of -$140,753,000.00 indicating challenges in its operations. The operating expenses amount to $25,996,000.00 encompassing various operational costs incurred in maintaining its services. Furthermore, the weighted average number of diluted shares outstanding is 63,199,000.00 reflecting potential dilution effects that could impact shareholders. The EBITDA is -$11,481,000.00 a key indicator of the company's operational profitability, showcasing its financial health in the biopharmaceutical landscape. In terms of market presence, the stock is affordable at $12.49 suitable for budget-conscious investors looking to enter this sector. The stock has a high average trading volume of 1,584,407.00 indicating strong liquidity, which may provide investors with confidence in the ease of trading shares. With a market capitalization of $798,901,617.00 the company is classified as a small-cap player, positioning it as a potentially agile competitor within its field. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation. Avid Bioservices, Inc. belongs to the Healthcare sector, where it continues to foster growth and development, addressing the evolving needs of biotechnology and biopharmaceutical enterprises.
What is Avid Bioservices, Inc. (CDMO)'s stock forecast?
Analysts predict Avid Bioservices, Inc. stock to fluctuate between $5.90 (low) and $12.51 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Avid Bioservices, Inc.'s market capitalization?
As of 2025-02-04, Avid Bioservices, Inc.'s market cap is $798,901,617, based on 63,963,300 outstanding shares.
How does Avid Bioservices, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Avid Bioservices, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Avid Bioservices, Inc. pay dividends?
Avid Bioservices, Inc. pays dividends. The current dividend yield is 25.34%, with a payout of $0.66 per share.
How can I buy Avid Bioservices, Inc. (CDMO) stock?
To buy Avid Bioservices, Inc. (CDMO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CDMO. Place an order (Market, Limit, etc.).
What is the best time to invest in Avid Bioservices, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Avid Bioservices, Inc. stock ever split?
Avid Bioservices, Inc.'s last stock split was 1:7 on 2017-07-10.
How did Avid Bioservices, Inc. perform in the last earnings report?
Revenue: $139,911,000 | EPS: -$2.23 | Growth: -24,877.78%.
Where can I find Avid Bioservices, Inc.'s investor relations reports?
Visit https://www.avidbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Avid Bioservices, Inc.?
You can explore historical data from here
What is the all-time high and low for Avid Bioservices, Inc. stock?
All-time high: $34.51 (2021-11-11) | All-time low: $2.24 (2018-02-15).
What are the key trends affecting Avid Bioservices, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
JERUSALEM , May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025.
newsfilecorp.com
First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis Process Rehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market.
proactiveinvestors.com
BioHarvest Sciences Inc. (NASDAQ:BHST) CEO Ilan Sobel joined Proactive to discuss the company's transition to stage two of its partnership with a pharmaceutical company. This marks a key milestone in the development of plant-derived biological materials for use in approved drugs.
proactiveinvestors.com
BioHarvest Sciences Inc. (NASDAQ:BHST) announced the successful transition of its contract development and manufacturing (CDMO) partnership with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, further validating its Botanical Synthesis technology for pharmaceutical applications. The contract, which began in early 2024, aims to develop a compound used in an approved drug product.
newsfilecorp.com
Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types Rehovot, Israel--(Newsfile Corp. - May 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed from Stage 1 to Stage 2 - providing further validation of the versatility of the Company's Botanical Synthesis platform to develop active pharmaceutical compounds while concurrently paving the road for potential future volume manufacturing. Stage 1 of the contract, launched in early 2024, focused on sourcing the required plants to develop a compound used to produce an approved drug product.
prnewswire.com
SHANGHAI , March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been recognized for excellence in "Best Scientific Expertise", "Best Seamless Delivery Across Phases", "Best Innovative Approach to Technology and Process Execution", making it the most lauded company in the ceremony.
accessnewswire.com
LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
accessnewswire.com
LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
accessnewswire.com
LOS ANGELES, CA / ACCESS Newswire / February 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
accessnewswire.com
LOS ANGELES, CA / ACCESS Newswire / February 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
See all news
